Alpha Cognition Announces Voluntary Delisting from CSE
13 December 2024 - 10:41AM
Business Wire
Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition”,
or the “Company”), announces that in connection with the Company’s
listing on the Nasdaq Capital Market the Company will voluntarily
delist its common shares from the Canadian Securities Exchange.
The shares will be delisted from the Canadian Securities
Exchange at the close of trading on December 17, 2024. The
Company’s common shares will continue to trade on the Nasdaq under
the symbol “ACOG”.
About Alpha Cognition Inc.
Alpha Cognition Inc. is a commercial stage, biopharmaceutical
company dedicated to developing treatments for patients suffering
from neurodegenerative diseases, such as Alzheimer’s disease and
Cognitive Impairment with mild Traumatic Brain Injury (“mTBI”), for
which there are currently no approved treatment options.
ZUNVEYL is a patented drug approved as a new generation
acetylcholinesterase inhibitor (AChEI) for the treatment of
Alzheimer’s disease, with expected minimal gastrointestinal side
effects. ZUNVEYL’s active metabolite is differentiated from
donepezil and rivastigmine in that it improves the function of
neuronal nicotinic receptors, most notably the alpha-7 subtype,
which is known to have a positive effect on cognition.
Benzgalantamine is also being developed in combination with
memantine to treat moderate to severe Alzheimer’s dementia, and as
an intranasal formulation for Cognitive Impairment with mTBI.
Forward-looking Statements: This news release includes
forward-looking statements within the meaning of applicable
securities laws. Except for statements of historical fact, any
information contained in this news release may be a forward‐looking
statement that reflects the Company’s current views about future
events and are subject to known and unknown risks, uncertainties,
assumptions and other factors that may cause the actual results,
levels of activity, performance or achievements to be materially
different from the information expressed or implied by these
forward-looking statements. Although the Company believes to have a
reasonable basis for each forward-looking statement, we caution you
that these statements are based on a combination of facts and
factors currently known by us and our expectations of the future,
about which we cannot be certain. The Company cannot assure that
the actual results will be consistent with these forward-looking
statements. These forward‐looking statements speak only as of the
date of this news release and the Company undertakes no obligation
to revise or update any forward‐looking statements for any reason,
even if new information becomes available in the future.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241212186439/en/
For further information: Michael McFadden, CEO Tel:
1-858-344-4375 info@alphacognition.com
Alpha Cognition (NASDAQ:ACOG)
Historical Stock Chart
From Nov 2024 to Dec 2024
Alpha Cognition (NASDAQ:ACOG)
Historical Stock Chart
From Dec 2023 to Dec 2024